HIV-1 entry at the mucosal surface: Role of antibodies in protection

AIDS

Volumn 14, Issue SUPPL. 3, 2000, Pages

  Mascola, J R ^a   Frankel, S S ^a   Broliden, K ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Antibody; HIV; Mucosal surface; SHIV; SIV

Indexed keywords

ANTIBODY RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; MUCOSAL IMMUNITY; PRIORITY JOURNAL; REVIEW;

ANIMALS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MUCOUS MEMBRANE;

EID: 0033781529     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. The science of AIDS: A tale of two worlds
2. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy
3. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA
4. CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue
5. + T cells
6. Breaching barriers
7. Human male genital tract immunity and experimental models
8. A rational basis for mucosal vaccination against HIV infection
9. HIV-1 transmission across the vaginal epithelium
10. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier
11. Mucosal events in the pathogenesis of human immunodeficiency virus type 1 infection
12. Transepithelial transport of HIV-1 by intestinal M cells: A mechanism for transmission of AIDS
13. Langerhans cells, macrophages and lymphocyte subsets in the cervix and vagina of rhesus macaques
14. The dendritic cell in clinical immunology: The AIDS example
15. Role of dendritic and follicular dendritic cells in HIV infection and pathogenesis
16. Role of dendritic cells in immunopathogenesis of human immunodeficiency virus infection
17. Dendritic cells route human immunodeficiency virus to lymph nodes after vaginal or intravenous administration to mice
18. Dendritic cells and the control of immunity
19. The role of dendritic cells in the induction and regulation of immunity to microbial infection
20. Mobilizing dendritic cells for tolerance, priming, and chronic inflammation
21. Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways
22. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1
23. Both a precursor and a mature population of dendritic cells can bind HIV
24. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells
25. 4+ T cells with the human immunodeficiency virus: Use of dendritic cells from individuals homozygous for the Delta32CCR5 allele as a model
26. Coexpression of NF-kappa B/Rel and Sp1 transcription factors in human immunodeficiency virus 1-induced, dendritic cell-T-cell syncytia
27. + T cells in response to antigen depends on close contact through adhesion molecules
28. HIV-1 selection by epidermal dendritic cells during transmission across human skin
29. SIV replication and the dendritic cell
30. DC-SIGN, a dendritic cell-specific HIV-1 binding protein that enhances trans-infection of T-cells
31. DC-SIGN: A guide to some mysteries of dendritic cells
32. The role of skin dendritic cells in the initiation of human immunodeficiency virus infection
33. Immature dendritic cells selectively replicate macrophagenic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-Tropic virus to T cells
34. + hematopoietic progenitor cells is primarily determined by their maturation stage
35. Expression and function of CCR5 and CXCR4 on human Lnagerhans cells and macrophages: Implications for HIV primary infection
36. Langerhans cell tropism of human immunodeficiency virus type 1 subtype A through F isolates derived from different transmission groups
37. Chronic inflammation with increased HIV RNA expression in the vaginal mucosa association with heterosexual transmission of HIV
38. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques
39. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus
40. Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid
41. T cell-tropic simian immunodeficiency virus (SIV) and simian-human immunodeficiency viruses are readily transmitted by vaginal inoculation of rhesus macaques, and Langerhans' cells of the female genital tract are infected with SIV
42. Identification of target cells in the cervicovaginal mucosa 18 hours after SIV inoculation
43. Mucosal immunity in the female genital tract
44. Perspective: Hypothesis: Serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum
45. Return to the past: The case for antibody-based therapies in infectious diseases
46. Summary of antibody workshop: The role of humoral immunity in the treatment and prevention of emerging and extant infectious diseases
47. Mucosal immune system of the human genital tract
48. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals
49. + T cells
50. + T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele
51. Protective immunity against HIV infection: Has nature done the experiment for us?
52. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures
53. Protective immunity to HIV-1 in SCID/beige mice reconstituted with peripheral blood lymphocytes of exposed but uninfected individuals
54. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
55. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons
56. Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type I highly exposed, persistently seronegative female sex workers in northern Thailand
57. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers
58. HIV IgA-specific neutralizing responses in mucosal samples from HIV-exposed, uninfected individuals
59. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity
60. Immunoglobulin A-induced shift of Ebstein-Barr virus tissue tropism
61. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM
62. High-level ability of secretory IgA to block HIV type 1 transcytosis: Contrasting secretory IgA and IgG responses to glycoprotein 160
63. Infectious human immunodeficiency virus can rapidly penetrate a tight human epithelial barrier by transcytosis in a process impaired by mucosal immunoglobulins
64. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins
65. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
66. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
67. Mechanisms of neutralization of influenza virus in tracheal epithelial and BHK cells vary according to IgG concentration
68. IgG surfaces as an important component in mucosal protection
69. Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG
70. Prevention of HIV infection by passive immunization with HIV immunoglobulin
71. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
72. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccinee sera
73. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
74. The role of nonhuman primates in the development of an AIDS vaccine
75. The consequence of passive administration of an anti-human immunodeficiency virus type I neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate
76. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
77. Infection of cynomolgus monkeys with a chimeric HIV-1/SIV virus that expresses the HIV-1 envelope glycoproteins
78. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV)
79. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells
80. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-Like disease after in vivo passage in rhesus monkeys
81. An env gene derived from a primary human immunodeficiency virus type I isolate confers high in vivo replicative capacity to a chimeric simian human immunodeficiency virus in rhesus monkeys
82. Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: Determinants of high virus loads and CD4 cell killing
83. Neutralizing antibody directed against the HIV-1 envelope glycoptotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
84. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
85. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
86. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
87. Progesterone implants enhance SIV vaginal transmission and early virus load